Rate My Professor Camille Esneau

Esneau's research portfolio, centered on virology (50%), respiratory diseases (20%), and innate immunity (30%), includes extensive use of advanced models such as air-liquid interface differentiated human airway epithelial cells to study viruses like rhinoviruses, SARS-CoV-2, and respiratory syncytial virus (RSV). Notable publications feature book chapters "Rhinovirus diversity and virulence factors" (2019) and "Rhinovirus structure, replication, and classification" (2019), alongside peer-reviewed articles such as "The Pandemic REspiratory Virus Epidemiological SurveillaNce Trial - A self-swab surveillance system for respiratory viruses nested within FluTracking" (Journal of Infectious Diseases, 2025), "Opportunities for rhinovirus-targeted RNA therapeutics: A narrative review" (CMI Communications, 2025), "Understanding Rhinovirus Circulation and Impact on Illness" (Viruses, 2022), "A persistent neutrophil-associated immune signature characterizes post–COVID-19 pulmonary sequelae" (Science Translational Medicine, 2022), "Human coronaviruses 229E and OC43 replicate and induce distinct antiviral responses in differentiated primary human bronchial epithelial cells" (American Journal of Physiology-Lung Cellular and Molecular Physiology, 2020), and "RSV hijacks cellular protein phosphatase 1 to regulate M2-1 phosphorylation and viral transcription" (PLoS Pathogens, 2018).